Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Hirsutism secondary prevention
Introduction
Overview
Overview
Effective measures for the secondary prevention of hirsutism include lifestyle modification and pharmacological prevention. The goal of secondary prevention is to prevent cardiovascular and metabolic diseases (diabetes mellitus).
Secondary Prevention
Secondary Prevention
- Effective measures for the secondary prevention of hirsutism include lifestyle modification and pharmacological prevention.
Lifestyle modification
- First-line non-pharmacological therapy to decrease future cardiovascular and metabolic diseases (diabetes mellitus)
- They have to be considered more in obese women with polycystic ovary syndrome (PCOS)
- They are better to combine with:
Pharmacological prevention
- Although the lifestyle modification is really decrease the risk of future diseases, but sometimes it will be necessary to add a medicine to lifestyle modification.
- These drugs are generally used for:
- Dyslipidemia with statins
- Metabolic syndrome, pre-diabetes or type 2 diabetes with insulin sensitizing agents
- Hypertension with anti-hypertensive agents
- Severe obesity with anti-obesity agents
- Studies suggest that obese women with PCOS may be less likely to develop hirsutism if they eat a low-calorie diet.[4]
References
References
- ↑ Karimzadeh MA, Javedani M (2010). “An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome”. Fertil. Steril. 94 (1): 216–20. doi:10.1016/j.fertnstert.2009.02.078. PMID 19463994.
- ↑ Graff SK, Mário FM, Alves BC, Spritzer PM (2013). “Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes”. Fertil. Steril. 100 (4): 1081–8. doi:10.1016/j.fertnstert.2013.06.005. PMID 23830153.
- ↑ Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P, Norman RJ (2009). “Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis”. Hum. Reprod. Update. 15 (1): 57–68. doi:10.1093/humupd/dmn043. PMID 18927072.
- ↑ Franks, Stephen (2012). “The investigation and management of hirsutism”. Journal of Family Planning and Reproductive Health Care. 38 (3): 182–186. doi:10.1136/jfprhc-2011-100175. ISSN 1471-1893.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rasam Hajiannasab M.D.[2] Eiman Ghaffarpasand, M.D. [3]